| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | July 23, 2026 | 6/12 | 1 high, 3 medium, 2 low flags | 1 | 0 | Call sheet → |
| Q4'25 | February 10, 2026 | 9/12 | 2 medium, 4 low flags | 4 | 2 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Pending | Progress trial results at TCT Confirmed for October presentation |
| Q2'26 | Pending | Next-gen Pascal approval Q4 in US/Europe Reaffirmed timeline |
| Q2'26 | Pending | Pascal Tricuspid U.S. launch in Q4 Still expecting Q4, no trial results yet |
| Q2'26 | Delivered | R&D at approximately 17% of sales Q2 at 16%, FY guidance maintained at 17% |
| Q2'26 | Pending | Operating margin at high end of 28-29% Reaffirmed despite gross margin pressure |
| Q2'26 | Pending | TMTT sales of $740-780M Raised low end to $760M, strong momentum |
| Q2'26 | Pending | TAVR sales of $4.7-5.0B (7-9% growth) Raised to $4.75-5.0B (8-9%), tracking ahead |
| Q2'26 | Pending | Full year 2026 sales growth of 9-11% On track, raised to 10-11% after Q2 |
| Q4'25 | Missed | Continue share repurchase activities opportunistically Only $40M in Q4 vs $800M+ earlier in year |
| Q4'25 | Missed | GennaValve regulatory process continuing through Q1 Deal completely failed to close, no explanation provided |
| Q4'25 | Delivered | Lower second half operating margins due to key investments Q4 margin of 23.7% vs Q3 27.5%, as warned |
| Q4'25 | Delivered | Mid-single digit surgical growth for 2025 4.3% full year growth, within promised range |
| Q4'25 | Delivered | TMTT sales guidance of $530-550M for full year Exceeded $500M for first time, within guided range |
| Q4'25 | Exceeded | Full year TAVR guidance of 6-7% raised to 7-8% in Q3 Delivered 10.6% TAVR growth in Q4, well above raised guidance |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.